Year: 2026
Type: article
Abstract: Contemporary dentistry faces recurring challenges in managing pain, modulating inflammation, and promoting tissue regeneration, especially in orofacial pain, periodontal diseases, and temporomandibular disorders. In this context, Cannabis sativa L. stands out as a promising medicinal ally. Historically used for multiple purposes, C. sativa L. was recently included in the Brazilian Common Denominations (DCB) list by Anvisa, legitimizing its therapeutic use in Brazil. Recent scientific advances have elucidated its mechanisms of action and primary phytocannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC). These substances interact directly with the endocannabinoid system (ECS), a key biological regulatory system. Notably, endocannabinoid receptors have been identified throughout the oral cavity, including the oral mucosa, dental pulp, periodontal tissues, salivary glands, and temporomandibular joints. Activation of the ECS in these structures offers new perspectives for effective dental approaches by providing targeted analgesia, inflammation control, and antimicrobial effects. Consequently, integrating cannabinoids into dental practice represents a significant path toward improving clinical outcomes and enhancing patients' quality of life during treatments.
Source: Revista Fitos
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7204129376